Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierWe are a fully integrated biopharmaceutical company focused on developing innovative medicines for people impacted by central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and developing differentiated products with a focus on novel mechanisms of action, that have the potential to transform patient outcomes.
In the company’s own words · 10-K filed Feb 23, 2026 · SEC EDGAR
Business segments
Q2 2026 · $3.1MThe company’s own SEC segment disclosure.
- Royalty And Milestone$2.0M66%
- Milestone$546.0K18%
- Royalty$500.0K16%
Axsome Therapeutics, Inc. (AXSM) reported revenue of $218M in Q2 2026 (quarter ended June 30, 2026), up 46% from the same quarter a year earlier. That came with a gross margin of 94% and net loss of $51M. For the full year FY2025, revenue was $638M (+66% year on year) and net income −$183M. Its largest product in 2026-Q2 was Royalty And Milestone at $2.0M, 66% of the disclosed total, just ahead of Milestone at 18%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.